

**Recombinant Viral Macrophage
Inflammatory Protein-2
(rViMIP-2)**
PrimeGene Technical Data Sheet

Catalog Number:	281-02
Source:	<i>Escherichia coli</i> .
Molecular Weight:	Approximately 8.0 kDa, a single, non-glycosylated polypeptide chain containing 70 amino acids.
Quantity:	10µg/50µg/1000µg
AA Sequence:	LGASWHRPDK CCLGYQKRPL PQVLLSSWYP TSQLCSKPGV IFLTKRGRQV CADKSKDWVK KLMQQLPVTA
Purity:	> 97 % by SDS-PAGE and HPLC analyses.
Biological Activity:	Fully biologically active when compared to standard. The specific activity is determined by the inhibitory effect on monocyte migration response to human MIP-1 alpha using a concentration range of 1.0µg-10.0µg/ml of viral MIP-2 will inhibit 25ng/ml of human MIP-1 alpha.
Physical Appearance:	Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation:	Lyophilized from a 0.2 µm filtered concentrated solution in 20 mM PB, pH 7.4, 150mM NaCl.
Endotoxin:	Less than 1 EU/µg of rViMIP-2 as determined by LAL method.
Reconstitution:	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Shipping:	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none">● 12 months from date of receipt, -20 to -70 °C as supplied.● 1 month, 2 to 8 °C under sterile conditions after reconstitution.● 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Usage:	This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

Viral Macrophage Inflammatory Protein-2

Viral MIP-2 is one of the three chemokine-like proteins expressed by the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus, KSHV) and the other is ViMIP-1 and ViMIP-3. It shares 41 % and 48 % with human MIP-1α and ViMIP-1, respectively. ViMIP-2 has been shown to have antagonist activity towards a wide range of chemokine receptors and has functions of blocking infection by several different human immunodeficiency virus type 1 (HIV-1) strains. It may form part of the response to host defenses contributing to virus-induced neoplasia and may have relevance to KSHV and HIV-1 interactions. Additionally, ViMIP-2 has been shown to activate and chemoattract human eosinophils.